Eikonizo Therapeutics

Cambridge, MA · Founded 2017 · Privately Held (backing)

Developer of brain-penetrant and peripherally-restricted small molecules designed to slow or modify the progression of neurodegenerative and cardiorenal diseases. Eikonizo Therapeutics is based in Cambridge, MA and was founded in 2017. It was valued at $54 million at its later-stage round in Dec 2023, the last priced event on record. It has raised $46.1 million across 2 recorded rounds; the latest was a $371,352 seed round in May 2018.

PMV mark · valuation
$54.0M
Oct 2026
Priced at
its later-stage round
Dec 2023
Total raised
$46.1M
Last round
Seed Round
May 2018

Who backs Eikonizo Therapeutics?

8 investors
InvestorType
National Institutes of HealthOther
F-Prime CapitalVenture capital
Johnson & Johnson Innovation - JLABSOther
Mission BioCapitalVenture capital
Alzheimers Drug Discovery Foundation—
Kevin Kinsella—
LabCentral—
Novo Nordisk—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Eikonizo Therapeutics investors

8 investors are on record for Eikonizo Therapeutics, including National Institutes of Health, F-Prime Capital, Johnson & Johnson Innovation - JLABS and Mission BioCapital. The seed round in May 2018 drew 1 investor.

Free account
More of Eikonizo Therapeutics with a free account
  • ·Watch Eikonizo Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 8 firms already write checks for companies like Eikonizo Therapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View